ORAL AZACITIDINE AS BRIDGING THERAPY FOR INTERMEDIATE/HIGH-RISK AML PATIENTS AWAITING ALLO-HSCT: A SINGLE-CENTER EXPERIENCE (SIE 2026) - Oct 6, 2026 - Abstract #DP201; Pres time: Sep 22, 2026; 06:30 PM - 07:30 PM; Location: AREA POSTER; "No patients were excluded from transplant due to azacitidine-related ad- verse events. Although our experience is limited to a small series, these data are encouraging for the use of oral azaciti- dine when allo-HSCT is delayed."
Clinical • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • FLT3
|
|
A. Carobene1; S. Marotta1; M. Pedata1; M. Celentano1; S. Leone1; I. Migliaccio1; C. Riccardi1; C. Luise1; S. Vitiello2; C. Falco3; R. Penta4; M. Salzano1; V. Oliva1; A. Picardi1,5
|